Does ischemic versus nonischemic etiology affect reverse LV remodeling and symptom benefit with CRT in patients with NYHA class III/IV heart failure?
Patients with nonischemic heart failure experience greater reverse LV remodeling and symptom benefit from CRT at 1 year compared to those with ischemic etiology.
Reverse LV remodeling and symptom benefit with CRT are sustained at 12 months in patients with New York Heart Association class III/IV heart failure but occur to a lesser degree in patients with an ischemic versus a nonischemic etiology, most likely owing to the inexorable progression of ischemic disease.
Sutton et al. (Tue,) studied this question.